Diagnostics Industry Sees Growth From Emerging Markets

Growth in the $54.6 billion in vitro diagnostics (IVD) market during 2013 came from emerging markets while developed nation markets grew at a much slower pace. All of the major IVD companies reported large increases in the top seven emerging markets. This is mostly fueled by privatization and health insurance initiatives by governments and employers. Medicare price cutting in the U.S. is expected to continue, and the IVD market in Europe should remain essentially flat for the next few years. 

According to Kalorama Information’s biennial survey of the IVD industry, The Worldwide Market for In Vitro Diagnostic Tests, 9th Edition, China, Brazil and Korea were among the countries that received industry interest in the form of acquisitions, partnerships and expanded sales efforts.

Topics: Diagnostics Healthcare

Veterinary Diagnostics: Disease Threats to Animals Continues to Boost Need for New Tests

The diseases that can affect cattle, pigs and other livestock and endanger the food supply are numerous, yet still growing. Swine fever, neosporosis, foot-and-mouth disease and other diseases are among the threats to animals that humans eat. Test makers have answered the call to develop products that can help food manufacturers and government agencies protect livestock and ensure a safe food supply at the beginning of the chain. For this reason, the Veterinary Diagnostics market can expect healthy revenue growth, according to insights from a Kalorama Information report on the topic.

Topics: Diagnostics Pets Kalorama Information

How The Myriad Genetics Patent Dispute Impacts The IVD Market

The recent Supreme Court ruling on the Myriad Genetics patent dispute was monumental for the IVD market.  Its 17-year monopoly on BRCA testing for genetic risk for breast, ovarian cancer was brought to an end.  According to Kalorama Information, this decision couldn't have come any sooner. In my opinion, they're right.

In plain terms, the Supreme Court ruled that a company can't patent genes that naturally exist. On the other hand, genes that are developed by a company in a lab comfortably fall under intellectual property protection.  This is good news for the sake of innovation and progress in the Cancer Diagnostics market. Human genes can't be patented.  It should be common sense, but we all know that common sense isn’t always common.

Topics: Diagnostics Biotechnology